

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 8/29/1947
Sex: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 01/01/2017 12:34

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 21-284-151496
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 1 of 3 | Printed: 8/19/2022 6:53:21 AM

ERBB2 (HER2/neu) (HercepTest) with Interpretation by Immunohistochemistry, Tissue

ARUP test code 0049174

ERBB2 (HercepTest) by IHC

1+ Negative

Controls were run and performed as expected.
This result has been reviewed and approved by [REDACTED]

[REDACTED]
2000 Circle of Hope, RM 3100
Salt Lake City, UT 84112

INTERPRETIVE INFORMATION: HercepTest

Breast Tumors:

The result of the HercepTest by Dako (Agilent) is interpreted in a semi-quantitative manner. Test is FDA-approved for breast and gastric cancer only, and performed on formalin-fixed,

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 21-284-151496
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 3 | Printed: 8/19/2022 6:53:21 AM

paraffin-embedded tissue. Antibody clone is polyclonal and uses a proprietary detection system.

ARUP Laboratories uses the 2018 ASCO/CAP guidelines for interpretation of ERBB2 (HER2) protein expression in breast cancers fixed in formalin for 6-72 hours with a cold ischemic time of less than 1 hour. Tissue not meeting these requirements or tissue placed in decalcification solution should be interpreted with caution due to the likelihood of false negative results.

Positive cases are those with uniform, intense, complete circumferential membrane staining of more than 10 percent of invasive tumor cells (score 3+). Negative cases are defined as a) no staining observed, or incomplete membrane staining that is faint or barely perceptible and is less than or equal to 10 percent of the invasive tumor cells (score 0), or b) incomplete membrane staining that is faint or barely perceptible and is greater than 10 percent of the invasive tumor cells (score 1+). Equivocal cases are those with weak to moderate complete membrane staining observed in greater than 10 percent of tumor cells (score 2+). Other rare staining patterns may be considered equivocal. It is recommended that an Equivocal result be reflexed to another method of testing.

For more information refer to the ASCO/CAP guidelines found at www.jco.org.

Controls stained appropriately.

Percent of Cells/Circumferential	0
Intensity of Staining	weak
Homogenous Pattern	Non Circum

VERIFIED/REPORTED DATES

Procedure	Accession	Collected	Received	Verified/Reported
ERBB2 (HER2) by FISH	21-284-151496	10/11/2021 1:49:00 PM	10/29/2021 1:48:45 PM	11/5/2021 7:00:00 PM
ERBB2 (HercepTest) by IHC	21-284-151496	10/11/2021 1:49:00 PM	11/3/2021 6:38:05 PM	11/4/2021 6:08:00 PM
Percent of Cells/Circumferential	21-284-151496	10/11/2021 1:49:00 PM	11/3/2021 6:38:05 PM	11/4/2021 6:08:00 PM
Intensity of Staining	21-284-151496	10/11/2021 1:49:00 PM	11/3/2021 6:38:05 PM	11/4/2021 6:08:00 PM
Homogenous Pattern	21-284-151496	10/11/2021 1:49:00 PM	11/3/2021 6:38:05 PM	11/4/2021 6:08:00 PM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 21-284-151496
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 3 of 3 | Printed: 8/19/2022 6:53:21 AM